---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-096173"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:51:07.963874+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports Q2 net loss $14.4M; terminates epetraborole Phase 2/3 trial in TR-MAC lung disease

## Summary
- Cash, equivalents, and investments $104.5M at June 30, 2024; runway through 2027.
- Net loss $14.4M in Q2 2024 vs $15.8M in Q2 2023; R&D $12.1M, G&A $3.7M.
- Terminated Phase 2/3 EBO-301 trial after sputum culture conversion at Month 6 similar between arms; PRO tool validated.
- Plans to advance AN2-502998 into Phase 1 for Chagas disease in 2025 and epetraborole into Phase 2 for melioidosis.
- Published study on epetraborole efficacy against M. abscessus mouse lung infection model in Antimicrobial Agents and Chemotherapy.

## SEC filing metadata
- accession: 0000950170-24-096173
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017024096173/0000950170-24-096173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017024096173/antx-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-096173
- JSON: https://secwatch.observer/filing/0000950170-24-096173.json
- Plain text: https://secwatch.observer/filing/0000950170-24-096173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.